Certolizumab pegol for the treatment of Crohn's disease.

By W. Sandborn, B. Feagan, S. Stoinov, P. J. Honiball, P. Rutgeerts, D. Mason, R. Bloomfield, Stefan Schreiber. New England Journal of Medicine, 2007

594 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/8c661c3fe3dd37fd6123378629c2feb3f56d36bd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Stefan Schreiber

In Immunology

1. Stefan Schreiber

In Rheumatology

1. Stefan Schreiber

Citations in the corpus

• Certolizumab pegol for the treatment of Crohn’s disease (2011, methodology): “Strategies for loss of response to infliximab or adalimumab as the first anti-TNF agent has been to increase the dose (infliximab) and/or increase the dosing frequency (infliximab and adalimumab) [Sandborn et al. 2009, 2007; Hanauer et al. 2002].”